Can Abbott Laboratories Beat Baxter International and Edwards Lifesciences in 2014?

The year 2013 proved to be a rather frustrating one for shareholders in Abbott Laboratories (NYSE: ABT  ) . Indeed, shares were outperformed by the S&P 500, with the index delivering capital gains of 32% while Abbott Laboratories managed only 19%.

However, Abbott Laboratories was not the only Healthcare Equipment stock to be handsomely beaten by the S&P 500. Sector peers Baxter International (NYSE: BAX  ) and Edwards Lifesciences (NYSE: EW  ) fared worse than Abbott Laboratories in 2013, posting returns of 6% and -26%, respectively.

This trend has, encouragingly, not continued thus far in 2014, with Edwards Lifesciences and Abbott Laboratories ahead of the index in 2014 (+3.2% and +2.4%, respectively), while Baxter International is down 1.3% -- just behind the S&P 500's return of -0.2% year to date. Can Abbott Laboratories beat its two main rivals (and the index) in 2014?

An unfair 2013?
It's often said that the stock market looks beyond the current year's earnings. However, for Abbott Laboratories in 2013, this was certainly not the case. Earnings per share (EPS) in 2013 were around 46% lower than they were in 2012, but don't be fooled - this drop was actually due to Abbott spinning out its pharmaceutical division into AbbVie at the start of 2013. However, adjusting for this spinoff, Abbott's sales for the year came in slightly below expectations and earnings were in line with analyst estimates; these weren't the kind of results that generally gets investors excited about a stock.

Despite this, forecasts for 2014 and 2015 remain very upbeat, with Abbott Laboratories expected to deliver EPS growth of 9% in 2014, and 12% in 2015. Both of these numbers are well ahead of the average growth rate for S&P 500 stocks in 2014 and 2015, showing that Abbott Laboratories could still offer potential upside.

A tough 2013 for the sector
Indeed, it appears as though the market was focused on 2013 for Baxter International, too, as shares had a tough year. However, as with Abbott Laboratories, upside potential remains, because Baxter International is forecast to increase EPS by 10% in 2014, and by 6% in 2015, which does not yet appear to be fully reflected in the company's share price.

Meanwhile, Edwards Lifesciences saw profit in the fourth quarter fall by 17% versus the fourth quarter of 2012 as a result of higher selling and administrative expenses, as well as a charge related to severance expenses. In addition, EPS forecasts appear to be mixed for Edwards Lifesciences, with EPS forecast to drop by 4% in 2014 before rising by 16% in 2015, thereby giving an annualized rate of 5.5% in 2014 and 2015.

Looking Ahead
Although 2013 was a disappointing year for shareholders of Abbott Laboratories, with it underperforming the S&P 500, the future looks bright due to strong growth forecasts in 2014 and 2015. The same can be said for Baxter International, with strong growth expected to be delivered in 2014 and 2015 after a challenging 2013. Edwards Lifesciences, meanwhile, may struggle to keep pace with its two sector peers due to its lower expected EPS growth rate and dampened market sentiment after its tough fourth quarter.

As for whether Abbott Laboratories can beat Baxter International in 2014, its higher EPS growth rate in 2014 and 2015 (combined) give it a good chance, although there seems to be little to choose between the two stocks. However, both look set to have a strong 2014, and have a good chance of reversing their underperformance of the S&P 500 in 2013.

Another top growth stock for 2014
It's not just Abbott Laboratories that stands out as a top growth stock in 2014. Furthermore, there's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report, "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Editor's Note: A previous version of this article incorrectly stated that Abbott Laboratories' EPS dropped 46% year over year and did not take the spinoff of Abbott's pharmaceutical division into account. The article has been updated and the Fool regrets the error.


Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 27, 2014, at 10:48 AM, klebad wrote:

    "Earnings per share (EPS) in 2013 were around 46% lower than they were in 2012". Maybe that was due to Abbott splitting into 2 companies at the start of 2013.

  • Report this Comment On February 28, 2014, at 9:09 AM, PEStudent wrote:

    "Earnings per share (EPS) in 2013 were around 46% lower than they were in 2012, which could have been why shares performed poorly relative to the wider index."

    PAY ATTENTION before writing an article! Abbott Labs split into Abbvie and Abbott Labs on the first business day of 2013. We shareholders got 1 share of ABBV for each share of ABT we owned and the Abbvie shares were initial priced at $35 compared to a split-adjust final 2012 price of $31.35 for ABT. Additionally, ABT bore much of the Long Term Debt after the split and was expected to grow more slowly as it took steps to increase it's margins in each category of sales to bring them up to competitors: and ABT made excellent improvements in 2013.

  • Report this Comment On March 05, 2014, at 10:27 AM, TMFMassimo wrote:

    @klebad, @PEStudent,

    Thanks for catching this error, we'll make a correction.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2855999, ~/Articles/ArticleHandler.aspx, 10/23/2014 2:50:11 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement